Jennifer M Knight

6PUBLICATIONS
41CO-AUTHORS
Social epidemiologyHaematologyMajor global burdens of diseasePredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 15, 2024
The health risk of social disadvantage is transplantable into a new host.

Lucie M Turcotte, Tao Wang, Kirsten M Beyer

|Apr 25, 2024
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Nandita Khera, Sikander Ailawadhi, Ruta Brazauskas

|Sep 29, 2023
Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis.

Mallory R Taylor, Steve W Cole, Joelle Strom

|May 23, 2022
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.

Jennifer M Knight, Aniko Szabo, Igli Arapi

|Jan 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

Jennifer M Knight, Erin S Costanzo, Suraj Singh

Pageof 1

Frequent Collaborators

2 joint publications

Lena E Winestone

2 joint publications

Parameswaran Hari

2 joint publications

Sherif M Badawy

2 joint publications

Jaime M Preussler